"Pyridinium Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of PYRIDINE containing a cation C5H5NH or radical C5H6N.
Descriptor ID |
D011726
|
MeSH Number(s) |
D03.383.725.762
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridinium Compounds".
Below are MeSH descriptors whose meaning is more specific than "Pyridinium Compounds".
This graph shows the total number of publications written about "Pyridinium Compounds" by people in this website by year, and whether "Pyridinium Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1998 | 0 | 2 | 2 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2006 | 1 | 1 | 2 |
2007 | 0 | 2 | 2 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2015 | 1 | 1 | 2 |
2016 | 1 | 1 | 2 |
2017 | 1 | 2 | 3 |
2018 | 0 | 3 | 3 |
2019 | 0 | 2 | 2 |
2020 | 1 | 1 | 2 |
2021 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridinium Compounds" by people in Profiles.
-
Labeling PIEZO2 activity in the peripheral nervous system. Neuron. 2023 08 16; 111(16):2488-2501.e8.
-
SIRT3 is required for liver regeneration but not for the beneficial effect of nicotinamide riboside. JCI Insight. 2021 04 08; 6(7).
-
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Clin Transl Sci. 2020 11; 13(6):1178-1188.
-
Epigenetic Targeting of TERT-Associated Gene Expression Signature in Human Neuroblastoma with TERT Overexpression. Cancer Res. 2020 03 01; 80(5):1024-1035.
-
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
-
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6839-6851.
-
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.
-
Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight. 2018 08 23; 3(16).
-
Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. Am J Manag Care. 2018 08; 24(16 Suppl):S356-S365.
-
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2018 02 01; 78(3):742-757.